Compare AVAH & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | NRIX |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | AVAH | NRIX |
|---|---|---|
| Price | $7.69 | $15.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $10.56 | ★ $29.46 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 03-12-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,290,591,000.00 | $83,980,000.00 |
| Revenue This Year | $21.81 | N/A |
| Revenue Next Year | $5.96 | $20.16 |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | 15.48 | ★ 53.95 |
| 52 Week Low | $3.67 | $8.18 |
| 52 Week High | $10.32 | $22.50 |
| Indicator | AVAH | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 43.33 |
| Support Level | $7.68 | $15.87 |
| Resistance Level | $8.63 | $17.01 |
| Average True Range (ATR) | 0.38 | 1.11 |
| MACD | -0.10 | -0.29 |
| Stochastic Oscillator | 10.98 | 20.88 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.